1. Home
  2. SANG vs SPRO Comparison

SANG vs SPRO Comparison

Compare SANG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

HOLD

Current Price

$5.06

Market Cap

170.0M

Sector

Technology

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.30

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANG
SPRO
Founded
1984
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.0M
136.7M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
SANG
SPRO
Price
$5.06
$2.30
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
4.1K
318.6K
Earning Date
02-04-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,360,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.08
$0.51
52 Week High
$7.99
$3.22

Technical Indicators

Market Signals
Indicator
SANG
SPRO
Relative Strength Index (RSI) 46.37 47.73
Support Level $5.03 $2.26
Resistance Level $5.42 $2.38
Average True Range (ATR) 0.09 0.08
MACD -0.02 -0.00
Stochastic Oscillator 42.28 54.76

Price Performance

Historical Comparison
SANG
SPRO

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: